Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeting BRCA1 And DNA Repair In Alzheimer’s To Prevent Or Reverse Symptoms

This article was originally published in Start Up

Executive Summary

New research has shown that levels of the DNA repair protein BRCA1 are reduced in key parts of neurons after amyloid formation. The findings are consistent with the amyloid hypothesis and could prove to be an effective way to help prevent or reverse the symptoms of Alzheimer’s disease and other neurodegenerative diseases.

You may also be interested in...



Discredited SIRT1 Stops DNA Damage In Neurons

SIRT1, the molecule activated by the controversial anti-aging supplement resveratrol, has been among the most disappointing of drug targets but now, research has linked it, along with the enzyme HDAC1, to the ability to stabilize the genome following DNA damage. The work is encouraging for the development of activators of SIRT1 and HDAC1 as neuroprotectants and DNA repair agents.

Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease

Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.

Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel